Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ANI PHARMACEUTICALS INCANIP · Entity 4638 | Director · PRESIDENT & CEO | September 15, 2026 | September 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ANI PHARMACEUTICALS INC
Report date September 15, 2026 · Filed September 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 339,089 |
Reported balance
After 2026-09-15 transaction · row 1
1 source rowRow 1 · 2026-09-15 · Sale · Disposed 5,400 · Balance 339,089 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 26, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 26, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 15, 2026 Filed Sep 16, 2026 20:20 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 5,400 | $71.00 | $383,400.00 |
DisclosureSEC source: 0001822629-26-000016 · wk-form4_1789590049.xml · nonDerivative · entry 1 Lalwani Nikhil · CIK 0001822629 · Director · PRESIDENT & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 339,089 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 26, 2026. Read SEC document |
| August 25, 2026 Filed Aug 26, 2026 22:15 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 5,400 | $74.30 | $401,220.00 |
DisclosureSEC source: 0001822629-26-000014 · wk-form4_1787782508.xml · nonDerivative · entry 1 Lalwani Nikhil · CIK 0001822629 · Director · PRESIDENT & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 344,489 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 26, 2026. F2 · price: The shares were sold in multiple trades at prices ranging from $73.58 to $74.61. The price reported above reflects the weighted average sales price. Read SEC document |
| May 11, 2026 Filed May 13, 2026 20:16 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 55,000 | $77.57 | $4,266,350.00 |
DisclosureSEC source: 0001822629-26-000011 · wk-form4_1778703381.xml · nonDerivative · entry 1 Lalwani Nikhil · CIK 0001822629 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 349,889 F1 · price: The shares were sold in multiple trades at prices ranging from $76.21 to $80.38. The price reported above reflects the weighted average sales price. Read SEC document |
| March 07, 2026 Filed Mar 10, 2026 20:09 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 17,060 | $74.04 | $1,263,122.40 |
DisclosureSEC source: 0001822629-26-000008 · wk-form4_1773173356.xml · nonDerivative · entry 1 Lalwani Nikhil · CIK 0001822629 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 404,889 F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 33,352 shares of restricted stock, the grant of which was previously reported. Read SEC document |
| February 28, 2026 Filed Mar 2, 2026 22:58 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 12,217 | $73.90 | $902,836.30 |
DisclosureSEC source: 0001822629-26-000006 · wk-form4_1772492331.xml · nonDerivative · entry 2 Lalwani Nikhil · CIK 0001822629 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 421,949 F2 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 23,883 shares of restricted stock, the grant of which was previously reported. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 22:58 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 75,592 | $77.15 | $5,831,922.80 |
DisclosureSEC source: 0001822629-26-000006 · wk-form4_1772492331.xml · nonDerivative · entry 1 Lalwani Nikhil · CIK 0001822629 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 434,166 F1 · kind: Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 26, 2026. Read SEC document |
| February 14, 2026 Filed Feb 17, 2026 21:07 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 10,298 | $77.36 | $796,653.28 |
DisclosureSEC source: 0001822629-26-000004 · wk-form4_1771362436.xml · nonDerivative · entry 2 Lalwani Nikhil · CIK 0001822629 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 358,574 F2 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 20,132 shares of restricted stock, the grant of which was previously reported on February 16, 2024. Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 21:07 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 11,688 | $76.70 | $896,469.60 |
DisclosureSEC source: 0001822629-26-000004 · wk-form4_1771362436.xml · nonDerivative · entry 1 Lalwani Nikhil · CIK 0001822629 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 368,872 F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 22,849 shares of restricted stock, the grant of which was previously reported on February 18, 2025. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 21:09 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 30,659 | $76.25 | $2,337,748.75 |
DisclosureSEC source: 0001822629-26-000002 · wk-form4_1771016985.xml · nonDerivative · entry 1 Lalwani Nikhil · CIK 0001822629 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 380,560 F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 63,686 performance stock units, the grant of which was previously reported on April 6, 2023. Read SEC document |
| August 12, 2025 Filed Aug 14, 2025 21:48 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 56,960 | $85.93 | $4,894,572.80 |
DisclosureSEC source: 0001822629-25-000010 · wk-form4_1755208123.xml · nonDerivative · entry 1 Lalwani Nikhil · CIK 0001822629 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 411,219 F1 · price: The shares were sold in multiple trades at prices ranging from $84.40 to $87.47. The price reported above reflects the weighted average sales price. Read SEC document |
| March 23, 2025 Filed Mar 25, 2025 20:47 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 17,455 | $64.26 | $1,121,658.30 |
DisclosureSEC source: 0001822629-25-000008 · wk-form4_1742935660.xml · nonDerivative · entry 1 Lalwani Nikhil · CIK 0001822629 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 468,179 F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 34,124 shares of restricted stock, the grant of which was previously reported. Read SEC document |
| March 07, 2025 Filed Mar 14, 2025 21:20 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 17,060 | $60.62 | $1,034,177.20 |
DisclosureSEC source: 0001822629-25-000006 · wk-form4_1741987242.xml · nonDerivative · entry 1 Lalwani Nikhil · CIK 0001822629 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 485,634 F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 33,352 shares of restricted stock, the grant of which was previously reported. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 22:10 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 12,216 | $61.89 | $756,048.24 |
DisclosureSEC source: 0001822629-25-000004 · wk-form4_1741126197.xml · nonDerivative · entry 1 Lalwani Nikhil · CIK 0001822629 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 502,694 F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 23,882 shares of restricted stock, the grant of which was previously reported. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 01:16 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 7,799 | $58.92 | $459,517.08 |
DisclosureSEC source: 0001822629-25-000002 · wk-form4_1739927772.xml · nonDerivative · entry 3 Lalwani Nikhil · CIK 0001822629 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 514,910 F3 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 20,132 shares of restricted stock, the grant of which was previously reported. Read SEC document |
| February 12, 2025 Filed Feb 19, 2025 01:16 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 60,932 | $0.00 | $0.00 |
DisclosureSEC source: 0001822629-25-000002 · wk-form4_1739927772.xml · nonDerivative · entry 2 Lalwani Nikhil · CIK 0001822629 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 522,709 F2 · kind: These shares represent performance stock units, which will vest over the applicable performance period based on the achievement of the provided performance targets, as set forth in the governing award agreement, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting. Read SEC document |
| February 12, 2025 Filed Feb 19, 2025 01:16 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 91,399 | $0.00 | $0.00 |
DisclosureSEC source: 0001822629-25-000002 · wk-form4_1739927772.xml · nonDerivative · entry 1 Lalwani Nikhil · CIK 0001822629 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 461,777 F1 · kind: Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 12, 2025. Read SEC document |
| November 26, 2024 Filed Nov 27, 2024 22:38 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Exercise / conversionStock Option (right to buy) · Derivative | 30,000 | $29.00 Strike: $29.00 | $870,000.00 |
DisclosureSEC source: 0001822629-24-000014 · wk-form4_1732747122.xml · derivative · entry 4 Lalwani Nikhil · CIK 0001822629 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,027 Underlying: Common Stock · 30,000 shares Expires 2030-09-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the total options vested on each of September 8, 2021, September 8, 2022, September 8, 2023 and September 8, 2024. Read SEC document |
| November 26, 2024 Filed Nov 27, 2024 22:38 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 3,481 | $58.30 | $202,942.30 |
DisclosureSEC source: 0001822629-24-000014 · wk-form4_1732747122.xml · nonDerivative · entry 3 Lalwani Nikhil · CIK 0001822629 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 370,378 F2 · price: The shares were sold in multiple trades at prices ranging from $58.18 to $58.61. The price reported above reflects the weighted average sales price. Read SEC document |
| November 26, 2024 Filed Nov 27, 2024 22:38 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 30,000 | $57.95 | $1,738,500.00 |
DisclosureSEC source: 0001822629-24-000014 · wk-form4_1732747122.xml · nonDerivative · entry 2 Lalwani Nikhil · CIK 0001822629 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 373,859 F1 · price: The shares were sold in multiple trades at prices ranging from $57.76 to $58.55. The price reported above reflects the weighted average sales price. Read SEC document |
| November 26, 2024 Filed Nov 27, 2024 22:38 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Exercise / conversionCommon Stock | 30,000 | $29.00 | $870,000.00 |
DisclosureSEC source: 0001822629-24-000014 · wk-form4_1732747122.xml · nonDerivative · entry 1 Lalwani Nikhil · CIK 0001822629 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 403,859 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 08, 2024 Filed Sep 10, 2024 20:44 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 3,646 | $60.51 | $220,619.46 |
DisclosureSEC source: 0001822629-24-000012 · wk-form4_1726001072.xml · nonDerivative · entry 1 Lalwani Nikhil · CIK 0001822629 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 373,859 F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 7,127 shares of restricted stock, the grant of which was previously reported. Read SEC document |
| May 14, 2024 Filed May 16, 2024 21:02 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 16,669 | $66.10 | $1,101,820.90 |
DisclosureSEC source: 0001822629-24-000010 · wk-form4_1715893316.xml · nonDerivative · entry 1 Lalwani Nikhil · CIK 0001822629 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 377,505 F1 · price: The shares were sold in multiple trades at prices ranging from $65.67 to $67.56. The price reported above reflects the weighted average sales price. Read SEC document |
| March 23, 2024 Filed Mar 25, 2024 20:09 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 17,455 | $69.58 | $1,214,518.90 |
DisclosureSEC source: 0001822629-24-000008 · wk-form4_1711397380.xml · nonDerivative · entry 1 Lalwani Nikhil · CIK 0001822629 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 394,174 F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 34,124 shares of restricted stock, the grant of which was previously reported. Read SEC document |
| March 08, 2024 Filed Mar 9, 2024 00:25 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 16,292 | $67.13 | $1,093,681.96 |
DisclosureSEC source: 0001822629-24-000006 · wk-form4_1709943903.xml · nonDerivative · entry 3 Lalwani Nikhil · CIK 0001822629 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 411,629 F3 · price: The shares were sold in multiple trades at prices ranging from $66.42 to $67.74. The price reported above reflects the weighted average sales price. Read SEC document |
| March 07, 2024 Filed Mar 9, 2024 00:25 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 17,060 | $66.71 | $1,138,072.60 |
DisclosureSEC source: 0001822629-24-000006 · wk-form4_1709943903.xml · nonDerivative · entry 2 Lalwani Nikhil · CIK 0001822629 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 427,921 F2 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 33,352 shares of restricted stock, the grant of which was previously reported. Read SEC document |
| March 06, 2024 Filed Mar 9, 2024 00:25 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 28,965 | $65.52 | $1,897,786.80 |
DisclosureSEC source: 0001822629-24-000006 · wk-form4_1709943903.xml · nonDerivative · entry 1 Lalwani Nikhil · CIK 0001822629 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 444,981 F1 · price: The shares were sold in multiple trades at prices ranging from $65.00 to $66.01. The price reported above reflects the weighted average sales price. Read SEC document |
| February 29, 2024 Filed Mar 1, 2024 22:06 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 10,014 | $67.67 | $677,647.38 |
DisclosureSEC source: 0001822629-24-000004 · wk-form4_1709330802.xml · nonDerivative · entry 1 Lalwani Nikhil · CIK 0001822629 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 473,946 F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 23,882 shares of restricted stock, the grant of which was previously reported. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:56 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 53,686 | $0.00 | $0.00 |
DisclosureSEC source: 0001822629-24-000002 · wk-form4_1708120602.xml · nonDerivative · entry 2 Lalwani Nikhil · CIK 0001822629 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 483,960 F2 · kind: These shares represent performance stock units, which will vest over the applicable performance period based on the achievement of the provided performance targets, as set forth in the governing award agreement, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:56 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 80,530 | $0.00 | $0.00 |
DisclosureSEC source: 0001822629-24-000002 · wk-form4_1708120602.xml · nonDerivative · entry 1 Lalwani Nikhil · CIK 0001822629 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 430,274 F1 · kind: Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 14, 2024. Read SEC document |
| September 08, 2023 Filed Sep 11, 2023 22:23 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 3,646 | $61.94 | $225,833.24 |
DisclosureSEC source: 0001822629-23-000004 · wk-form4_1694471020.xml · nonDerivative · entry 1 Lalwani Nikhil · CIK 0001822629 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 349,744 F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 7,127 shares of restricted stock, the grant of which was previously reported. Read SEC document |
| August 15, 2023 Filed Aug 16, 2023 00:39 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Exercise / conversionStock Option (right to buy) · Derivative | 11,616 | $29.00 Strike: $29.00 | $336,864.00 |
DisclosureSEC source: 0001822629-23-000002 · wk-form4_1692146335.xml · derivative · entry 4 Lalwani Nikhil · CIK 0001822629 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 168,027 Underlying: Common Stock · 11,616 shares Expires 2030-09-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the total options vested on each of September 8, 2021 and September 8, 2022. 25% of the total options will vest on each of September 8, 2023 and September 8, 2024. Read SEC document |
| August 15, 2023 Filed Aug 16, 2023 00:39 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 11,616 | $61.13 | $710,086.08 |
DisclosureSEC source: 0001822629-23-000002 · wk-form4_1692146335.xml · nonDerivative · entry 3 Lalwani Nikhil · CIK 0001822629 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 353,390 F1 · price: Reflects the weighted average price of sales on August 15, 2023. The shares were sold in multiple transactions at prices ranging from $60.68 to $61.87, inclusive. Read SEC document |
| August 15, 2023 Filed Aug 16, 2023 00:39 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Exercise / conversionCommon Stock | 11,616 | $29.00 | $336,864.00 |
DisclosureSEC source: 0001822629-23-000002 · wk-form4_1692146335.xml · nonDerivative · entry 2 Lalwani Nikhil · CIK 0001822629 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 365,006 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 11, 2023 Filed Aug 16, 2023 00:39 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 56,666 | $57.75 | $3,272,461.50 |
DisclosureSEC source: 0001822629-23-000002 · wk-form4_1692146335.xml · nonDerivative · entry 1 Lalwani Nikhil · CIK 0001822629 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 353,390 Read SEC document |
| March 23, 2023 Filed Mar 28, 2023 00:01 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 17,455 | $37.82 | $660,148.10 |
DisclosureSEC source: 0001104659-23-037250 · tm2310677-2_4seq1.xml · nonDerivative · entry 1 Lalwani Nikhil · CIK 0001822629 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,840 F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 34,124 shares of restricted stock, the grant of which was previously reported. Read SEC document |
| March 07, 2023 Filed Mar 9, 2023 23:44 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 4,265 | $44.23 | $188,640.95 |
DisclosureSEC source: 0001104659-23-030706 · tm239061-2_4seq1.xml · nonDerivative · entry 2 Lalwani Nikhil · CIK 0001822629 · Director · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,295 F2 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 8,338 shares of restricted stock, the grant of which was previously reported. Read SEC document |
| March 07, 2023 Filed Mar 9, 2023 23:44 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 9,397 | $44.23 | $415,629.31 |
DisclosureSEC source: 0001104659-23-030706 · tm239061-2_4seq1.xml · nonDerivative · entry 1 Lalwani Nikhil · CIK 0001822629 · Director · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,560 F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 25,013 shares of restricted stock, the grant of which was previously reported. Read SEC document |
| February 28, 2023 Filed Apr 5, 2023 00:10 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 63,686 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-041742 · tm2311710-9_4seq1.xml · nonDerivative · entry 2 Lalwani Nikhil · CIK 0001822629 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 410,056 F2 · kind: These shares represent performance stock units, which will vest over the applicable performance period based on the achievement of the provided performance targets, as set forth in the governing award agreement, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting. Read SEC document |
| February 28, 2023 Filed Apr 5, 2023 00:10 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 95,530 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-041742 · tm2311710-9_4seq1.xml · nonDerivative · entry 1 Lalwani Nikhil · CIK 0001822629 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 346,370 F1 · kind: Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 28, 2023. Read SEC document |
| September 08, 2022 Filed Sep 13, 2022 00:15 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 3,646 | $37.61 | $137,126.06 |
DisclosureSEC source: 0001415889-22-009569 · form4-09122022_050932.xml · nonDerivative · entry 1 Lalwani Nikhil · CIK 0001822629 · Director · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,957 F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 7,127 shares of restricted stock, the grant of which was previously reported. Read SEC document |
| April 27, 2022 Filed Apr 29, 2022 22:32 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 33,352 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-004403 · form4-04292022_030445.xml · nonDerivative · entry 1 Lalwani Nikhil · CIK 0001822629 · Director · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285,603 F1 · kind: Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of March 7, 2022. Read SEC document |
| March 24, 2022 Filed Mar 29, 2022 00:46 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 100,055 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-003392 · form4-03282022_050347.xml · nonDerivative · entry 1 Lalwani Nikhil · CIK 0001822629 · Director · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,251 F1 · kind: Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of March 7, 2022. Read SEC document |
| March 23, 2022 Filed Mar 26, 2022 00:52 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 17,454 | $27.03 | $471,781.62 |
DisclosureSEC source: 0001415889-22-003380 · form4-03252022_050311.xml · nonDerivative · entry 1 Lalwani Nikhil · CIK 0001822629 · Director · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,196 F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 34,123 shares of restricted stock, the grant of which was previously reported. Read SEC document |
| March 21, 2022 Filed Mar 24, 2022 01:05 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | PurchaseCommon Stock | 7,224 | $27.69 | $199,997.16 |
DisclosureSEC source: 0001415889-22-003308 · form4-03232022_060333.xml · nonDerivative · entry 1 Lalwani Nikhil · CIK 0001822629 · Director · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,650 F1 · price: The shares were acquired in multiple trades at prices ranging from $26.885 to $27.8058. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| September 08, 2021 Filed Sep 10, 2021 21:36 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 2,577 | $28.20 | $72,671.40 |
DisclosureSEC source: 0001415889-21-004348 · form4-09102021_020924.xml · nonDerivative · entry 1 Lalwani Nikhil · CIK 0001822629 · Director · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,426 F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 7,127 shares of restricted stock, the grant of which was previously reported. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 20:43 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 136,495 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-001659 · form4-03252021_010352.xml · nonDerivative · entry 1 Lalwani Nikhil · CIK 0001822629 · Director · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,003 F1 · kind: Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of March 23, 2021. Read SEC document |
| September 08, 2020 Filed Sep 10, 2020 22:18 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantStock Option (right to buy) · Derivative | 179,643 | $0.00 Strike: $29.00 | $0.00 |
DisclosureSEC source: 0001415889-20-002285 · form4-09102020_030939.xml · derivative · entry 2 Lalwani Nikhil · CIK 0001822629 · Director · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,643 Underlying: Common Stock · 179,643 shares Expires 2030-09-08 F2 · derivative.exercise_date: The option will vest and become exercisable as to 25% of the total shares on each of September 8, 2021, September 8, 2022, September 8, 2023 and September 8, 2024. Read SEC document |
| September 08, 2020 Filed Sep 10, 2020 22:18 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 28,508 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-20-002285 · form4-09102020_030939.xml · nonDerivative · entry 1 Lalwani Nikhil · CIK 0001822629 · Director · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,508 F1 · shares: Represents a restricted stock award that will vest as to 25% of the total shares on each of September 8, 2021, September 8, 2022, September 8, 2023 and September 8, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.